Products for Research Use Only
RegisterLogin

Levonadifloxacin

CAT: 0804-HY-14926-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14926-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Levonadifloxacin ((S) - (-) -Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin -susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].
CAS Number
154357-42-3
Product Name Alternative
(S) - (-) -Nadifloxacin; WCK 771
UNSPSC
12352005
Hazard Statement
H301
Target
Antibiotic; Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/levonadifloxacin.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CN2[C@@H](C)CCC3=C2C(C1=O)=CC(F)=C3N4CCC(O)CC4)O
Molecular Formula
C19H21FN2O4
Molecular Weight
360.38
Precautions
H301
References & Citations
[1]Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68 (12) :1716-1722. |[2]Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63 (8) :e00909-19.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

CatalogName
BA1115-10Levonadifloxacin
T88547-01Levonadifloxacin arginine
MBS5777522Levonadifloxacin Arginine Salt
9267Levonadifloxacin LND 10 µg

Popular Products